Radioprotection of hematopoietic progenitors by low dose amifostine prophylaxis

International Journal of Radiation Biology

Volumn 90, Issue 7, 2014, Pages 594-604

  Seed, Thomas M ^a   Inal, Cynthia E ^b   Singh, Vijay K ^b,c  

^a Tech Micro Services   (United States)

^b ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

^c Uniformed Services University of the Health Sciences   (United States)

Author keywords

Amifostine; Bone marrow; Hematopoietic progenitors; Radiation; Radioprotectants; WR2721

Indexed keywords

AMIFOSTINE;

ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BONE MARROW; BONE MARROW SUPPRESSION; C3H/HE MOUSE; CELL REGENERATION; CHEMOPROPHYLAXIS; COBALT THERAPY; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; HEMATOPOIETIC TISSUE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENITOR CELL LINE; RADIATION PROTECTION; STEADY STATE; WHOLE BODY RADIATION;

AMIFOSTINE; BONE MARROW; HEMATOPOIETIC PROGENITORS; RADIATION; RADIOPROTECTANTS; WR2721;

AMIFOSTINE; ANIMALS; BONE MARROW CELLS; HEMATOPOIETIC STEM CELLS; MALE; MICE; PROTO-ONCOGENE PROTEINS C-KIT; RADIATION-PROTECTIVE AGENTS;

EID: 84903728783     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2014.899450     Document Type: Article

References (57)

1. Benjamin GC, McGeary M, McCutchen SR. 2009. Assessing medical preparedness to respond to a terrorist nuclear event: Workshop report. Washington, DC: The National Academies Press.
2. Blankenbecler R. 2010. Low-dose pretreatment for radiation therapy. Dose Response 8: 534-542.
3. Brechignac F, Paquet F. 2013. Radiation-induced risks at low dose: Moving beyond controversy towards a new vision. Radiat Environ Biophys 52 : 299-301.
4. Brown DQ, Graham WJ 3rd, MacKenzie LJ, Pittock JW 3rd, Shaw LM. 1988. Can WR-2721 be improved upon? Pharmacol Therapeut 39 : 157-168.
5. Calabrese EJ. 2001. Overcompensation stimulation: A mechanism for hormetic effects. Crit Rev Toxicol 31: 425-470. (Pubitemid 32706310)
6. Capizzi RL. 1999. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26 : 3-21. (Pubitemid 29246624)
7. Capizzi RL, Oster W. 2000. Chemoprotective and radioprotective effects of amifostine: An update of clinical trials. Int J Hematol 72 : 425-435.
8. Carter RE, Verrllei DM. 1973. AFRRI cobalt whole-body irradiation. Technical Note 73-3. Bethesda, MD: Armed Forces Radiobiology Research Institute.
9. Coleman CN, Blakely WF, Fike JR, MacVittie TJ, Metting NF, Mitchell JB, Moulder JE, Preston RJ, Seed TM, Stone HB, Tofilon PJ, Wong RS. 2003. Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: Report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiat Res 159: 812-834. (Pubitemid 36676875)
10. Cortdy M. 1995. Murine colony assay (BFU-E, CFU-GM, CFU-GEMM). Stem cell technologies, Vancouver, BC, Canada.
11. Davidson DE, Grenan MM, Sweeney TR. 1980. Biological characteristics of some improved radioprotectors. In: Brady LW, editor. Radiation sensitizers. Their use in the clinical management of cancer. New York: Masson.
12. Day TK, Zeng G, Hooker AM, Bhat M, Turner DR, Sykes PJ. 2007. Extremely low doses of X-radiation can induce adaptive responses in mouse prostate. Dose Response 5: 315-322.
13. Dorr RT. 1998. Radioprotectants: Pharmacology and clinical applications of amifostine. Semin Radiat Oncol 8 : 10-13. (Pubitemid 28487528)
14. Fatome M, Courteille F, Laval JD, Roman V. 1987. Radioprotective activity of ethylcellulose microspheres containing WR 2721, after oral administration. Int J Radiat Biol Rel Stud Phys, Chem Med 52: 21-29. (Pubitemid 17104595)
15. Ferguson CD, Potter WC, Sands A, Spector LS, Wehling FL. 2004. The four faces of nuclear terrorism. Monterey, CA: Center for Nonproliferation Studies, Monterey Institute of International Studies Nuclear Threat Initiative.
16. Giambrarresi LI, Walker RI. 1989. Prospects of radioprotection. In: Office of the Surgeon General, DOTA, USA. Medical Consequences of Nuclear Warfare. Falls Church, VA: TMM Publications.
17. Grdina DJ, Murley JS, Kataoka Y, Epperly W. 2002. Relationships between cytoprotection and mutation prevention by WR-1065. Milit Med 167 : 51-53. (Pubitemid 34174183)
18. Greenberger JS. 2008. Gene therapy approaches for stem cell protection. Gene Ther 15 : 100-108.
19. Held KD, Awad S. 1991. Effects of polyamines and thiols on the radiation sensitivity of bacterial transforming DNA. Int J Radiat Biol 59 : 699-710.
20. Institute of Laboratory Animal Resources-Commission on Life Sciences, NRC. 1996. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press.
21. Khodarev NN, Kataoka Y, Murley JS, Weichselbaum RR, Grdina DJ. 2004. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC). Int J Radiat Oncol, Biol, Phys 60: 553-563. (Pubitemid 39233477)
22. Landauer MR, Davis HD, Dominitz JA, Weiss JF. 1987. Dose and time relationships of the radioprotector WR-2721 on locomotor activity in mice. Pharmacol, Biochem Behav 27: 573-576. (Pubitemid 17107034)
23. Landauer MR, Davis HD, Dominitz JA, Weiss JF. 1988a. Comparative behavioral toxicity of four sulfhydryl radioprotective compounds in mice: WR-2721, cysteamine, diethyldithiocarbamate, and N-acetylcysteine. Pharmacol Therapeut 39: 97-100.
24. Landauer MR, Davis HD, Dominitz JA, Weiss JF. 1988b. Long-term effects of radioprotector WR-2721 on locomotor activity and body weight of mice following exposure to ionizing radiation. Toxicology 49 : 315-323.
25. Landauer MR, Davis HD, Kumar KS, Weiss JF. 1992. Behavioral toxicity of selected radioprotectors. Adv Space Res 12 : 273-283.
26. Lechpammer S, Epperly MW, Zhou S, Nie S, Glowacki J, Greenberger JS. 2005. Adipocyte differentiation in Sod2(-/-) and Sod2(+/+) murine bone marrow stromal cells is associated with low antioxidant pools. Experim Hematol 33 : 1201-1208. (Pubitemid 41416968)
27. Ledney GD, Elliott TB, Harding RA, Jackson WE 3rd, Inal CE, Landauer MR. 2000. WR-151327 increases resistance to Klebsiella pneumoniae infection in mixed-field- and gamma-photon-irradiated mice. Int J Radiat Biol 76: 261-271. (Pubitemid 30093473)
28. Mazur L. 1996. Effects of sulphur-containing compounds and X-rays on the mouse erythropoietic system assayed by in-vivo peripheral blood micronucleus test. Strahlenther Onkol 172 : 25-29. (Pubitemid 26046468)
29. Meijne EI, Ploemacher RE, Huiskamp R. 1996. Sensitivity of murine haemopoietic stem cell populations to X-rays and 1 MeV fission neutrons in vitro and in vivo under hypoxic conditions. Int J Radiat Biol 70 : 571-577. (Pubitemid 26388948)
30. Meijne EI, van der Winden-van Groenewegen RJ, Ploemacher RE, Vos O, David JA, Huiskamp R. 1991. The effects of x-irradiation on hematopoietic stem cell compartments in the mouse. Exp Hematol 19:617-623.
31. Mitchel RE. 2006. Low doses of radiation are protective in vitro and in vivo: Evolutionary origins. Dose Response 4: 75-90.
32. Murley JS, Constantinou A, Kamath NS, Grdina DJ. 1997. WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Proliferat 30 : 283-294. (Pubitemid 28029936)
33. Myska JC, Adams TL, Bhatt RC, Broom JG, Pitcher CD, Sharpnack FM, St John TJ, Torres BA, Vavrina G, Gerstenberg HM. 1997. Arrays for use at the cobalt irradiation facility. Technical Report97-2. Bethesda, M D: Armed Forces Radiobiology Research Institute.
34. North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P. 2000. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 19 : 1206-1214. (Pubitemid 30157551)
35. Orlic D, Fischer R, Nishikawa S, Nienhuis AW, Bodine DM. 1993. Purification and characterization of heterogeneous pluripotent hematopoietic stem cell populations expressing high levels of c-kit receptor. Blood 82 : 762-770. (Pubitemid 23221654)
36. Pamujula S, Graves RA, Freeman T, Srinivasan V, Bostanian LA, Kishore V, Mandal TK. 2004. Oral delivery of spray dried PLGA/amifostine nanoparticles. J Pharmacy Pharmacol 56: 1119-1125. (Pubitemid 39207192)
37. Pamujula S, Kishore V, Rider B, Fermin CD, Graves RA, Agrawal KC, Mandal TK. 2005. Radioprotection in mice following oral delivery of amifostine nanoparticles. Int J Radiat Biol 81: 251-257. (Pubitemid 40911075)
38. Patchen ML, D'Alesandro MM, Chirigos MA, Weiss JF. 1988. Radioprotection by biological response modifiers alone and in combination with WR-2721. Pharmacol Therapeut 39: 247-254.
39. Patchen ML, MacVittie TJ. 1994. Granulocyte colony-stimulating factor and amifostine (Ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Semin Oncol 21 : 26-32. (Pubitemid 24356448)
40. Patchen ML, MacVittie TJ, Weiss JF. 1990. Combined modality radioprotection: The use of glucan and selenium with WR-2721. Int J Radiat Oncol, Biol, Phys 18: 1069-1075. (Pubitemid 20182339)
41. Pellmar TC, Rockwell S. 2005. Priority list of research areas for radiological nuclear threat countermeasures. Radiat Res 163 : 115-123. (Pubitemid 40039952)
42. Piper JR, Stringfellow CR Jr, Elliott RD, Johnston TP. 1969. S-2-(omegaaminoalkylamino) ethyl dihydrogen phosphorothioates and related compounds as potential antiradiation agents. J Medicinal Chem 12 : 236-243.
43. Ploemacher RE, van Os R, van Beurden CA, Down JD. 1992. Murine haemopoietic stem cells with long-term engraftment and marrow repopulating ability are more resistant to gamma-radiation than are spleen colony forming cells. Int J Radiat Biol 61: 489-499.
44. Purdie JW, Inhaber ER, Schneider H, Labelle JL. 1983. Interaction of cultured mammalian cells with WR-2721 and its thiol, WR-1065: Implications for mechanisms of radioprotection. Int J Radiat Biol Rel Stud Phys, Chem Med 43: 517-527. (Pubitemid 13054148)
45. Ramdas J, Warrier RP, Scher C, Larussa V. 2003. Effects of amifostine on clonogenic mesenchymal progenitors and hematopoietic progenitors exposed to radiation. J Pediatric Hematol/Oncol 25 : 19-26. (Pubitemid 36070960)
46. Seed T, Kumar S, Whitnall M, Srinivasan V, Singh V, Elliott T, Landauer M, Miller A, Chang CM, Inal C, Deen J, Gehlhaus M, Jackson W 3rd, Hilyard E, Pendergrass J, Toles R, Villa V, Miner V, Stewart M, Benjack J, Danilenko D, Farrell C. 2002a. New strategies for the prevention of radiation injury: Possible implications for countering radiation hazards of long-term space travel. J Radiat Res 43(Suppl.): S239-244.
47. Seed TM. 2005. Radiation protectants: Current status and future prospects. Health Phys 89: 531-545. (Pubitemid 41463887)
48. Seed TM, Fry SA, Neta R, Weiss JF, Jarrett DG, Thomassen D. 2002b. Prevention and treatments: Summary statement. Milit Med 167: 87-93. (Pubitemid 34174193)
49. Singh VK, Seed TM. 2003. Radiation effects. In: Roy MJ, editor. Physician's guide to terrorist attack. Totowa, NJ: Humana Press.
50. Srinivasan V, Pendergrass JA Jr, Kumar KS, Landauer MR, Seed TM. 2002. Radioprotection, pharmacokinetic and behavioural studies in mouse implanted with biodegradable drug (amifostine) pellets. Int J Radiat Biol 78: 535-543. (Pubitemid 34680785)
51. Srinivasan V, Weiss JF, Kumar KS. 1992. Radioprotection by combinations of WR-151327, vitamin E and selenomethionine. Proc 40th Annual Meeting of the Radiation Research Society.
52. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, Dynan WS, Fike JR, Grdina DJ, et al. 2004. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res 162: 711-728. (Pubitemid 39552901)
53. Turrisi AT, Glover DJ, Hurwitz S, Glick J, Norfleet AL, Weiler C, Yuhas JM, Kligerman MM. 1986. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]. Cancer Treat Rep 70: 1389-1393. (Pubitemid 17005117)
54. Walker RI. 1988. Requirements of radioprotectors for military and emergency needs. Pharmacol Therapeut 39: 13-20.
55. Weiss JF. 1997. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ Health Perspect 105(Suppl. 6): 1473-1478. (Pubitemid 28050944)
56. Weiss JF, Srinivasan V, Kumar KS, Landauer MR. 1992. Radioprotection by metals: Selenium. Adv Space Res 12: 223-231.
57. Whitnall MH, Wilhelmsen CL, McKinney L, Miner V, Seed TM, Jackson WE 3rd. 2002. Radioprotective efficacy and acute toxicity of 5-androstenediol after subcutaneous or oral administration in mice. Immunopharmacol Immunotoxicol 24 : 595-626. (Pubitemid 36008319)